Exploiting Tumor Hypoxia with Tirapazamine
Author Information
Author(s): JM Brown
Primary Institution: Mayer Cancer Biology Laboratory, Department of Radiation Oncology, Stanford University School of Medicine
Hypothesis
Can tirapazamine effectively target hypoxic tumor cells and enhance the efficacy of cisplatin?
Conclusion
Tirapazamine can turn the low oxygen levels in solid tumors from a disadvantage into an advantage by selectively killing hypoxic tumor cells.
Supporting Evidence
- Tirapazamine selectively kills hypoxic tumor cells without increasing the toxicity of cisplatin.
- Approximately 70% of tumors had lower oxygen levels than normal tissues.
- Tirapazamine's effectiveness is independent of the p53 status of the tumor cells.
Takeaway
Tirapazamine is a special medicine that can kill cancer cells that don't have enough oxygen, making it work better with another medicine called cisplatin.
Methodology
The study involved measuring oxygen levels in tumors from patients with squamous cell cancer using a polarographic needle electrode.
Limitations
No clinical trials have been conducted to confirm the effects of tirapazamine with chemotherapy.
Participant Demographics
Patients with squamous cell cancer of the head and neck.
Want to read the original?
Access the complete publication on the publisher's website